Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry
Abstract Introduction This study aimed to assess the incidence of hematologic malignancy (HM) among inflammatory arthritis (IA) patients receiving tumor necrosis factor inhibitors (TNFi) compared with the general Turkish population. Methods HUR-BIO (Hacettepe University Rheumatology Biologic Registr...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2023-06-01
|
| Series: | Rheumatology and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40744-023-00563-z |
| _version_ | 1797784454018629632 |
|---|---|
| author | Emine Duran Zeynep Ozge Ozturk Emre Bilgin Yahya Büyükaşık Omer Dizdar Gozde Kubra Yardimci Bayram Farisogullari Zehra Özsoy Gizem Ayan Gullu Sandal Uzun Mustafa Ekici Erdinc Unaldi Levent Kilic Ali Akdoğan Omer Karadag Şule Apraş Bilgen Sedat Kiraz Umut Kalyoncu Ali Ihsan Ertenli |
| author_facet | Emine Duran Zeynep Ozge Ozturk Emre Bilgin Yahya Büyükaşık Omer Dizdar Gozde Kubra Yardimci Bayram Farisogullari Zehra Özsoy Gizem Ayan Gullu Sandal Uzun Mustafa Ekici Erdinc Unaldi Levent Kilic Ali Akdoğan Omer Karadag Şule Apraş Bilgen Sedat Kiraz Umut Kalyoncu Ali Ihsan Ertenli |
| author_sort | Emine Duran |
| collection | DOAJ |
| description | Abstract Introduction This study aimed to assess the incidence of hematologic malignancy (HM) among inflammatory arthritis (IA) patients receiving tumor necrosis factor inhibitors (TNFi) compared with the general Turkish population. Methods HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single-center biological disease-modifying anti-rheumatic drug (bDMARD) registry since 2005. Patients with IA, including rheumatoid arthritis, spondyloarthritis, or psoriatic arthritis who had at least one visit after the TNFi were screened from 2005 to November 2021. Standardized incidence rates (SIR) were calculated after adjustment for age and gender and compared with the 2017 Turkish National Cancer Registry (TNCR). Results Of the 6139 patients registered in the HUR-BIO, 5355 used any TNFi at least once. The median follow-up duration was 2.6 years for patients receiving TNFi. Thirteen patients developed a HM on follow-up. In these patients, the median age at the IA onset was 38 (range, 26–67), and the median age at the HM diagnosis was 55.5 (range, 38–76). Patients using TNFi had an increased HM incidence (SIR 4.23, 95% confidence interval (CI) 2.35–7.05). Ten patients with HM were under 65 years of age. In this group, there was a higher incidence of HM in both men (SIR 5.15, 95% CI 1.88–11.43) and women (SIR 4.76, 95% CI 1.74–10.55). Conclusions The risk of HMs in inflammatory arthritis patients receiving TNFi was four times higher than in the general Turkish population. |
| first_indexed | 2024-03-13T00:40:06Z |
| format | Article |
| id | doaj.art-d6be86e826924b9c80491bed6fee8c46 |
| institution | Directory Open Access Journal |
| issn | 2198-6576 2198-6584 |
| language | English |
| last_indexed | 2024-03-13T00:40:06Z |
| publishDate | 2023-06-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Rheumatology and Therapy |
| spelling | doaj.art-d6be86e826924b9c80491bed6fee8c462023-07-09T11:24:28ZengAdis, Springer HealthcareRheumatology and Therapy2198-65762198-65842023-06-0110496998110.1007/s40744-023-00563-zHematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO RegistryEmine Duran0Zeynep Ozge Ozturk1Emre Bilgin2Yahya Büyükaşık3Omer Dizdar4Gozde Kubra Yardimci5Bayram Farisogullari6Zehra Özsoy7Gizem Ayan8Gullu Sandal Uzun9Mustafa Ekici10Erdinc Unaldi11Levent Kilic12Ali Akdoğan13Omer Karadag14Şule Apraş Bilgen15Sedat Kiraz16Umut Kalyoncu17Ali Ihsan Ertenli18Division of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDepartment of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Hematology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDepartment of Medical Oncology, Hacettepe University Cancer InstituteDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineDivision of Rheumatology, Department of Internal Medicine, Hacettepe University Faculty of MedicineAbstract Introduction This study aimed to assess the incidence of hematologic malignancy (HM) among inflammatory arthritis (IA) patients receiving tumor necrosis factor inhibitors (TNFi) compared with the general Turkish population. Methods HUR-BIO (Hacettepe University Rheumatology Biologic Registry) is a single-center biological disease-modifying anti-rheumatic drug (bDMARD) registry since 2005. Patients with IA, including rheumatoid arthritis, spondyloarthritis, or psoriatic arthritis who had at least one visit after the TNFi were screened from 2005 to November 2021. Standardized incidence rates (SIR) were calculated after adjustment for age and gender and compared with the 2017 Turkish National Cancer Registry (TNCR). Results Of the 6139 patients registered in the HUR-BIO, 5355 used any TNFi at least once. The median follow-up duration was 2.6 years for patients receiving TNFi. Thirteen patients developed a HM on follow-up. In these patients, the median age at the IA onset was 38 (range, 26–67), and the median age at the HM diagnosis was 55.5 (range, 38–76). Patients using TNFi had an increased HM incidence (SIR 4.23, 95% confidence interval (CI) 2.35–7.05). Ten patients with HM were under 65 years of age. In this group, there was a higher incidence of HM in both men (SIR 5.15, 95% CI 1.88–11.43) and women (SIR 4.76, 95% CI 1.74–10.55). Conclusions The risk of HMs in inflammatory arthritis patients receiving TNFi was four times higher than in the general Turkish population.https://doi.org/10.1007/s40744-023-00563-zHematologic malignancyTNF inhibitorsSpondyloarthritisRheumatoid arthritisPsoriatic arthritis |
| spellingShingle | Emine Duran Zeynep Ozge Ozturk Emre Bilgin Yahya Büyükaşık Omer Dizdar Gozde Kubra Yardimci Bayram Farisogullari Zehra Özsoy Gizem Ayan Gullu Sandal Uzun Mustafa Ekici Erdinc Unaldi Levent Kilic Ali Akdoğan Omer Karadag Şule Apraş Bilgen Sedat Kiraz Umut Kalyoncu Ali Ihsan Ertenli Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry Rheumatology and Therapy Hematologic malignancy TNF inhibitors Spondyloarthritis Rheumatoid arthritis Psoriatic arthritis |
| title | Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry |
| title_full | Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry |
| title_fullStr | Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry |
| title_full_unstemmed | Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry |
| title_short | Hematologic Malignancy Risk in Inflammatory Arthritis Patients Treated with TNF Inhibitors: The Real-Life Data from the HUR-BIO Registry |
| title_sort | hematologic malignancy risk in inflammatory arthritis patients treated with tnf inhibitors the real life data from the hur bio registry |
| topic | Hematologic malignancy TNF inhibitors Spondyloarthritis Rheumatoid arthritis Psoriatic arthritis |
| url | https://doi.org/10.1007/s40744-023-00563-z |
| work_keys_str_mv | AT emineduran hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT zeynepozgeozturk hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT emrebilgin hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT yahyabuyukasık hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT omerdizdar hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT gozdekubrayardimci hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT bayramfarisogullari hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT zehraozsoy hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT gizemayan hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT gullusandaluzun hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT mustafaekici hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT erdincunaldi hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT leventkilic hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT aliakdogan hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT omerkaradag hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT suleaprasbilgen hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT sedatkiraz hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT umutkalyoncu hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry AT aliihsanertenli hematologicmalignancyriskininflammatoryarthritispatientstreatedwithtnfinhibitorsthereallifedatafromthehurbioregistry |